Sort   by:  
 Page size 
ProteomicsBRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK
Erythropoiesis is a crucial part in hematopoietic system, while facing disruptions from various diseases conditions. Anemia and blood shortages has become global challenges, with current finite pharmacological options like EPO or glucocorticoids having limitations, especially in genetic anemias like...
ORGANISM(S): Homo Sapiens 
2024-09-09 | PXD055730 |
TranscriptomicsExpression data from MDCK cells exposed to HGF +/- MAPK inhibitors
Gene expression in Madin Darby canine kidney cells grown for 7 days to confluence on Transwell filters and exposed to HGF +/- inhibitors of the MAPK pathway (MAPK is one of the pathways activated when HGF binds to the CMET receptor tyrosine kinase). We used microarrays to detail the program of gene ...
ORGANISM(S): Canis lupus familiaris 
2010-05-25 | E-GEOD-9435 | biostudies-arrayexpress
GenomicsMetabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair [MAPK inhibitors]
Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair [MAPK inhibitors]
PRJNA973618 | ENA
GenomicsCombination treatment with BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma
Combination treatment with BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma
PRJNA723029 | ENA
GenomicsCombinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma
Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma
PRJNA913583 | ENA
GenomicsDrug-class specific gene-based MAPK sensitivity scores predict sensitivity to MAPK inhibitors in pediatric low-grade gliomas
Drug-class specific gene-based MAPK sensitivity scores predict sensitivity to MAPK inhibitors in pediatric low-grade gliomas
PRJNA923658 | ENA
GenomicsBRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (ATAC-Seq)
BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (ATAC-Seq)
PRJNA1085317 | ENA
GenomicsBRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (RNA-Seq)
BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (RNA-Seq)
PRJNA1085318 | ENA
GenomicsSuppression of heparan sulfation resensitizes YAP1-driven BRAF mutant melanoma to MAPK pathway inhibitors
Suppression of heparan sulfation resensitizes YAP1-driven BRAF mutant melanoma to MAPK pathway inhibitors
PRJNA797810 | ENA
GenomicsCOP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway [NGS1609]
COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway [NGS1609]
PRJNA840920 | ENA
Sort   by:  
 Page size